☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
KEYNOTE-181 study
Merck Reports Improved Overall Survival Results of Keytruda (pembrolizumab) vs Chemotherapy in KEYNOTE-181 Study
November 15, 2018
Load more...
Back to Home